# Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

> **NCT00977054** · PHASE4 · TERMINATED · sponsor: **National Taiwan University Hospital** · enrollment: 59 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** DFPP + Peg-IFN + RBV
- **DRUG:** Peg-IFN + RBV

## Key facts

- **NCT ID:** NCT00977054
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Novel HCV DAA approved by FDA
- **Last updated:** 2012-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977054, "Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00977054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*